Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice

Bobes, Julio; Rubio, Gabriel; Terán, Antonio; Cervera, G.; López-Gómez, V.; Vilardaga, I.; Pérez, Marta Real

doi:10.1016/j.eurpsy.2010.12.004

Cited by 53 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anecdotally, however, the benefit of the use of pregabalin seems a natural progression; from the evidence relating to alcohol and benzodiazepine withdrawal (Bobes et al, 2012;Nicola et al, 2010).…”

Section: Significancementioning

confidence: 98%

Pregabalin for detoxification from opioids: a single case study

Scanlon¹

2014

Mental Health and Substance Use

View full text Add to dashboard Cite

The objective of this research is to develop a clearer understanding as to whether pregabalin is an appropriate and efficacious method to treat individuals presenting with withdrawal symptoms following cessation of opiate drug abuse. The focus of this study is to identify the value of a particular medicine within a particular case, representative of a particular group. The author has identified the participant in advance of the study to meet criteria of opiate dependence and will explore the dynamics of the case in great detail. The sample for this study was a purposive sample of one female lady who has been diagnosed as opiate dependent (DSM-IV criteria). The analysis of data is an inductive cyclical process that involves a process of observing the particular phenomenon from more general to specific observations. Data analysis commenced with interviews with the patient with emphasis on history taking, information gathering, and treatment. Data analysis will include a crosstabulation of the subjective and objective data and the measurement of change using an evidence-based rating scale. The Clinical Opiate Withdrawal Scale was used to compare the analysis of the presenting symptoms longitudinally. From the objective data, it was a reasonable assumption that the symptoms of withdrawal were controlled better with pregabalin for the subject of this study. The patient acknowledged that this detoxification episode was "a lot easier than previous ones". It was a positive response in relation to the prescription of pregabalin that she first of all completed the prescribed detoxification regime and second it was acknowledged that the symptoms were alleviated more effectively than previous detoxification episodes.

show abstract

Section: Significancementioning

confidence: 98%

Pregabalin for detoxification from opioids: a single case study

Scanlon¹

2014

Mental Health and Substance Use

View full text Add to dashboard Cite

show abstract

“…Two robust studies, a 12-week, prospective, observational, multicenter study including 282 patients [36,68], and a 12-week, randomized, double-blind, placebo-controlled trial including 106 patients [70], have found that PGN is effective in reducing withdrawal and anxiety symptoms, as well as sleep parameters, cognitive and psychomotor functioning, and to a lesser extent it helps in achieving the maintenance of BZD abstinence. According to the studies reviewed, PGN's required dosage range in BD seems to be much higher (by more than 70%) than in AUD.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, significant and clinically relevant improvements in withdrawal (p<0.0001) and anxiety (p<0.0001) symptoms, as well as patient's global functioning were observed associated to PGN treatment. The authors concluded that because the improvement in anxiety symptoms in the study, especially the physic symptoms, was clinically relevant as early as the first week, this rapid onset of the anxiolytic effect of PGN may play an essential role in the subsequent success of BZD withdrawal [36,68]. In a secondary analysis of this study, the authors found that PGN was also effective in improving subjective sleep quality in this population group, measured with the Medical Outcomes Study Sleep Scale (MOS Sleep Scale).…”

Section: Pregabalin: Pregabalin (Pgn) (S)-3-(aminomethyl)-5-methyl-mentioning

confidence: 99%

Anticonvulsant Agents for the Management of Benzodiazepine Dependence

Marín-Mayor¹,

López‐Muñoz²,

Rubio³

2014

AAD

View full text Add to dashboard Cite

IntroductionChronic use of Benzodiazepines (BZDs) can lead to tolerance and dependence, as indicated by a BZD Withdrawal Syndrome (BWS). In general, it is preferred a gradual than an abrupt tapering of BZDs as a first step in the treatment of BZD Dependence (BD). In addition, a great variety of agents have been used as adjuvant medication for BD. Recently, research has focused in the use of Anticonvulsant (AC) drugs. The aim of this article is to review the use of AC in the management of BWS and BD. MethodsMEDLINE and the Cochrane were searched, selecting studies from 1980 until 2014, in which a pharmacological intervention with classic and new AC was made for discontinuing long-term BZD use. ResultsIn regard to classic AC, there were identified 10 studies related to carbamazepine and 4 studies related to valproate. On one hand, whereas there is a great body of research involving carbamazepine and there is a consensus about its efficacy for discontinuing long-term BZD use, especially in terms of improving drug-free outcomes, there have been brought inconclusive results in regard to valproate. On the other hand, studies identified of the new AC are as follows: 2 for gabapentin, 2 for oxcarbazepine, 2 for pregabalin, 1 for tigabine and 2 for topiramate. With the exception of pregabalin, only small studies and cases report have been conducted for most of the new AC. Pregabalin has demonstrated to be effective in the treatment of BD and BWS, exerting its beneficial action by reducing the severity of withdrawal and anxiety symptoms. ConclusionTo date, among AC agents, only carbamazepine and pregabalin can be considered as augmentation alternatives for the treatment of long-term BZD use. Further randomized, double-blind, placebo-controlled studies are necessary to increase the knowledge to support the use of AC for the treatment of BD and BWS.

show abstract

“…Так, J. Bobes и соавт. [7] отметили его эф-фективность при купировании бензодиазепиновой и алкогольной абстиненции, G. Martinotti и соавт. [8], M. Di Nicola и соавт.…”

Section: частота идентификации разных павunclassified